Key result
Decreasing or undetectable CMV-IE1 T cells post-transplant identify kidney recipients with ~81% CMV replication risk.
Why the study?
The diagnostic value of CMV-specific T cells for risk stratification of CMV replication in kidney transplant recipients needs implementation beyond CMV serostatus alone.
Does monitoring CMV-specific T cell kinetics predict CMV replication in kidney transplant recipients?
Comparison
Monitoring CMV-specific T cell kinetics vs CMV serostatus alone
Design
Cohort study measuring CMV-specific T cells by interferon-γ Elispot assay
Follow-up
+3 months posttransplantation
Authors
Loading...
CMV-specific T-cell kinetics may refine posttransplant CMV risk stratification beyond serostatus alone; leaves open whether prospective monitoring improves outcomes.
Cohort (n=326)
Does monitoring CMV-specific T cell kinetics predict CMV replication in kidney transplant recipients?
p-value: p=<0.001
Monitoring CMV-specific T cell kinetics offers superior risk stratification for CMV replication in kidney transplant recipients compared with CMV serostatus alone.
Maik Stein (2017) conducted a cohort in Kidney transplant recipients at risk of CMV replication (n=326). Decreasing or undetectable CMV-IE1-specific T cells vs. Stable or increasing CMV-IE1-specific T cells was evaluated on CMV replication (p=<0.001). Decreasing or undetectable CMV-IE1-specific T cells from pre- to post-transplantation identified kidney transplant recipients at increased risk of CMV replication (81% in R+ KTRs; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: